For many people living with serious psychiatric disorders, daily life is shaped by medication schedules, symptom management and long-term care.
Yet one of the biggest threats they face is often less visible. Physical illness, particularly heart disease and metabolic problems, continues to shorten lives well beyond what psychiatric treatment alone has been able to prevent.
A recent editorial in the journal Expert Opinion on Pharmacotherapy argues that a familiar class of drugs may help address this long-standing problem.
A gap medicine has not closed
People with schizophrenia, bipolar disorder and major depressive disorder consistently experience higher rates of obesity, diabetes and cardiovascular disease than the general population.
Also read: Research shows hobbies can strengthen mental health
These conditions, rather than mental illness itself, account for much of the excess and premature mortality seen in this group.
Despite advances in antipsychotics and mood stabilisers, overall life expectancy for people with severe mental illness has not meaningfully improved.
The editorial, authored by psychiatrist Roger McIntyre, highlights the urgent need for treatments that directly target physical health risks alongside psychiatric care.
Why GLP-1 drugs are being reconsidered
GLP-1 receptor agonists, widely used for type 2 diabetes and obesity, have been shown to improve blood sugar control, reduce weight and lower cardiovascular risk.
Also read: Early trial explores vaccine-based cancer prevention
These effects align closely with the health challenges faced by people with severe mental illness, particularly those experiencing medication-related weight gain and metabolic disease.
Rather than replacing psychiatric treatments, the editorial positions GLP-1 drugs as supportive therapies aimed at extending healthspan and reducing preventable deaths.
Early evidence also suggests potential benefits in managing substance use disorders and protecting kidney function, though these areas require further study.
Promise with limits
The editorial stresses caution. Side effects, kidney function, muscle loss and access issues must be carefully considered in this population. Cost and equitable availability remain major hurdles.
Also read: Health expert outlines reasons for frequent night urination
Still, the authors argue that GLP-1 receptor agonists represent one of the most promising tools in years for addressing the physical health burden tied to severe mental illness.
Sources: News Medical and Tandfonline
Also read: New study shows when fitness and strength begin to decline